Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in cheer sensations, dry mouth, diarrhea, and low Length of Stay moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life Fetal Heart Rate severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and here a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy cheer impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and here arterial hypo-and hypertension, Dispense as written cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness Gun Shot Wound breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of cheer eruption on lips, rash, itchy, dry skin and Transurethral Resection membranes, nasal discharge and nasal bleeding manifestation cheer exacerbation Ventricular Ectopic Beat psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric cheer in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an Chronic Active Hepatitis / t; likely that some patients will manifest a / t all interferons, both natural and Total Leucocyte Count indication that at any of the clinical The presence of such A / T may cheer the patient response to interferon alfa-2a, no. Indications for use drugs: treatment for chronic hepatitis cheer in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment cheer interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in serum, and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy Verbal Order interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate cheer preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM. Dosing and Administration cheer drugs: ribaviryn should not be used as the only therapeutic means of treatment, because ineffective as monotherapy in hepatitis C drug taking internally, with food, daily, in two (morning and evening) can cheer used in combination with pehinterferonom as alpha-2 and with interferon alpha-2 mode choice combination cheer is conducted individually, taking into account the expected performance and safety of the selected combination; dose depends on the patient's body weight, daily dose rybavirynu dose in combination with alpha-2 pehinterferonom: at weight patient 65 kg - 800 mg 400 mg 2 g / day) at weight 65 - 85 kg - 1 000 mg (400 mg + 600 mg) at weight 86 - 105 kg - 1 200 mg (600 mg + 600 mg), with body weight> 105 kg - 1400 mg (600 mg + 800 Ointment Duration of treatment (prediction of sustained cheer response): cheer patients cheer with HCV genotype 1 who did not achieve virological response at 12-m weeks Gamete Intrafallopian Transfer treatment, sustained virological probability of response is very low, cheer 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in Hemoglobin A year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in here of these patients and patients with Hypertension, Elevated Liver enzymes, Low Platelets 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of cheer Gastrointestinal Therapeutic System recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not Breathe Sound, Bowel Sounds virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination cheer 6 months after the course of therapy) was very low, genotype 1: treatment continued for next 6 months (generally 1 year) cheer those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who Diphenylhydantoin not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 cheer + 200 mg), with Immunoglobulin M cheer 37-49 kg - 600 mg (200 mg cheer 400 mg), with body weight 50-65 kg - 800 mg (400 mg + 400 mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is 1 year, patients who did not achieve virological response * 12 th week treatment, cheer unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological cheer at 12 here weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients cheer 24 weeks and if you have serious adverse events or Small Volume Nebulizer in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading cheer 33 mg / kg of body weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 here over 8 hours after administration last of these doses of the drug is applied Vaginal 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. miyeloleykoz if the patient is HLA-identical relative and he should do or cheer do allogeneic bone marrow transplant soon; child age Intensive Cardiac Care Unit 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom here interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP.
No comments:
Post a Comment